BPIFB4 and glioblastoma: As we herein showed that LAV-BPIFB4 blunts the degree of the senescence of cancer cells, we speculated that LAV-BPIFB4-treated U87-MG cells may also show high sensitivity to TMZ, the first-choice chemotherapeutic agent in GBM.